Participants in the study were patients being followed up in the Stroke Prevention Clinic or the Premature Atherosclerosis Clinic at University Hospital, London, Ontario, Canada. Participants were screened for this study by measurement of their carotid TPA. 15 We
T o be cost-effective, therapy to prevent cardiovascular events is best targeted to high-risk patients. Risk scores, such as the Framingham score, have been widely used for this purpose, but often misclassify risk. 1 Measurement of the burden of preclinical atherosclerosis has, therefore, been proposed as a way to improve cardiovascular prevention. 1 Although carotid intima-media thickness (IMT) has been widely used for the past 30 years, it is increasingly clear that IMT does not truly assess atherosclerosis 2, 3 and is a weak predictor of cardiovascular events, 4 that it is not feasible to measure progression of IMT within individuals in clinically meaningful time frames, and in large groups IMT progression does not predict events. 5 Quantification of plaque burden is superior to IMT for several reasons: it is a stronger predictor of cardiovascular events, [6] [7] [8] change can be reliably measured within individuals in months, [9] [10] [11] and progression of total plaque area (TPA) strongly predicts stroke, death, and myocardial infarction (MI). 12 Measurement of TPA has been used to treat arteries rather than risk factors, 10 and doing so markedly reduces cardiovascular events. 13 Volumetric measurement of plaque burden is much more closely correlated to coronary calcium than is IMT, 14 and 3-dimensional (3D) measurement of total plaque volume (TPV) is much more sensitive to effects of therapy than TPA 11 ; compared to IMT, measuring TPV reduces by two orders of magnitude the sample size and duration of followup required to study effects of new anti-atherosclerotic therapies. 11 It is expected that measurement of 3D plaque volume will be even more useful than TPA in treatment of atherosclerosis.
Here, we report results of the first study to assess prediction of cardiovascular events by progression of TPV and the first to compare progression/regression of carotid IMT, TPA, and TPV in patients attending vascular prevention clinics.
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recruited participants with a baseline plaque area between 40 and 600 mm 2 of TPA to ensure that participants would have measurable plaque volume and to ensure the ability to measure plaque progression or regression.
Participants gave written consent to a protocol approved by the Western University Human Ethics Research Board. They attended the research clinic at baseline and 1 year later for measurement of the ultrasound phenotypes described below, and annually for a total follow-up of 5 years for ascertainment of outcomes.
Ascertainment of Outcomes
At each annual visit, participants were queried about any events in the previous year. Any report of stroke, transient ischemic attack (TIA), MI, or revascularization (stenting, bypass, or endarterectomy of any artery) was confirmed by review of the hospital electronic record. For patients who could not be contacted to attend for follow-up because they had died, death and cause of death were confirmed by contact with the primary care physician.
Ultrasound Phenotypes
Carotid TPA, TPV, and IMT were measured at baseline and after 1 year. The observer (T.W.) was blinded to treatment and time point (baseline versus follow-up) for IMT and TPV. Measurements of TPA were performed on the ultrasound screen, not offline, so they were performed on the day of clinic visits, and, therefore, not blinded as to time. The technologists performing the plaque measurements were not aware of the treatments. 
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Total Plaque Area
TPA was measured by 2 experienced registered vascular technologists, using Phillips duplex scanners (ATL 5000 HDI with a L12-5, 50 mm transducer, using Sono-CT compound imaging; Advanced Technology Laboratories, Bothel, WA). As previously described, 15, 16 plaque was defined as a focal thickening of the intima-media layer, >1 mm in thickness. All plaques seen from the clavicle to the angle of the jaw, including the right subclavian artery and both common, internal and external carotid arteries, were measured. Each plaque was measured in a longitudinal view, selecting the plane in which the plaque seemed to have the largest footprint, and the cross-sectional area measured by tracing the perimeter of the plaque on the screen with a cursor driven by a trackball. The sum of the areas of all plaques seen was the TPA. Intraobserver reliability was 94% for repeated measurements; interobserver reliability on repeat scanning by the 2 technologists was 85%.
15
Total Plaque Volume
As previously described, 17, 18 TPV was measured with a software update permitting semiautomated segmentation of the lumen.
19,20 3D US images were acquired by translating the ultrasound transducer (L12-5, 50 mm, Philips, Bothel, WA) in a transverse orientation (perpendicular to the axis of flow) along the neck of the patient for ≈8 seconds an approximate distance of 4.0 cm, whereas video frames from the duplex scanner were digitized using 3DEchotec equipment (General Electric Medical Systems, Halbergmoos, Germany) coupled to the ATL HDI 5000 scanner. Cross-sectional slices were acquired at the rate of ≈30 slices/s, and saved to a computer workstation. The orientation and speed of the transducer was adjusted so that the resulting transverse 2D images were approximately parallel to each other with a mean spatial interval of ≈0.15 mm. The acquired 2D images were reconstructed immediately into a 3D US image and displayed using 3D viewing software (3DQuantify, Robarts Imaging Laboratories, London, Canada).
A semiautomated approach that uses 2 planes was used to quantify carotid plaque volume as previously described. 20 Plaque was defined as focal thickening >1 mm of the intima-media in the longitudinal view. Briefly, a longitudinal axis was set parallel to the axis of flow in the common and internal carotid arteries. Plaques were measured in the common carotid and internal carotid, from 1.5 cm below the bifurcation to 1 cm above the bifurcation. In a longitudinal view, the plane in which the plaque seemed to have the largest footprint was selected to identify the length and end points of the plaque. Along this length the plaque boundary was identified at 25%, 50%, and 75% of the total length using a second plane perpendicular to arterial blood flow. Although the longitudinal view identified the length and end points of the plaque, the perpendicular cross-sectional view defined plaque morphology. Individual plaque volumes within the same artery were summed to generate a TPV for 1 side. Intraobserver reliability for measurement of TPV is 94%, and interobserver reliability is 93%. 9 As previously described, 18 carotid TPVs were summed from left and right carotid arteries to generate a TPV for each subject at a particular time point.
Intima-Media Thickness
As previously described, 21 IMT was measured from lateral image planes extracted from the 3D US images. Images were included for analysis only if there was a clear intima-media layer present for measurement. In the 3D US image, a lateral plane parallel to the axis of the common carotid artery was selected from the location of the carotid bulb marked, and contrast and brightness optimized for viewing the intima-media layer. Calibration lines were drawn over a length of 10 mm, and a 24-bit bitmap was saved and imported into Prowin 24.0 (Medical Technologies International Inc, Palm Desert, CA). After calibration, measurements were obtained from a 10-mm segment of the far wall of the common carotid artery, 5 mm from the carotid bulb. A different segment was chosen if plaque was identified in that location (defined as focal thickening >1 mm). In some cases where there was diffuse thickening, the IMT exceeded 1 mm. A mouse-driven cursor was used to place 10 to 15 points along the media-adventitia and the intima-lumen boundary. The distance between the curves defined by the points was IMT. Measurements were repeated 3× per image, and the mean was calculated. Intraobserver reliability was 97.1%; interobserver reliability was not assessed.
Statistical Methods
Analyses were performed using IBM SPSS Statistics version 20 (IBM, Chicago, IL). A Kolmogorov-Smirnov test of normality showed that continuous variables were not normally distributed, hence median and interquartile range were reported for descriptive statistics, and a Kruskal-Wallis test was used to test for differences among groups. Categorical variables were reported as percentages and a χ 2 test (Exact test) used to test for differences. Progression or regression of TPA, TPV, or IMT was defined by tertiles of change from baseline to 1 year later. Kaplan-Meier survival analysis was performed to assess event rate by progression, stability, or regression of the ultrasound variables; comparisons among groups were by the log-rank test pooled over strata. Cox regression, using a backward stepwise Wald approach, was used to evaluate effects of covariates: age, sex, smoking status, serum total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, systolic blood pressure, and diabetes mellitus.
Results
There were 349 patients enrolled in the study. The median duration of follow-up was 3.17 years, with a maximum of 5.0 and a minimum of 0.07 years. The timing of dropouts and events is shown in Figure IV in the online-only Data Supplement. During 5 years, there were 21 dropouts. For each case the first qualifying event was used in the survival analyses. There were 50 first events: 20 vascular deaths, 11 strokes, 13 TIAs, and 6 MIs. Timing of first events is shown in Figure IV in the online-only Data Supplement. Some participants had >1 event; Table IV in the online-only Data Supplement shows the timing of all 55 events.
Baseline characteristics are shown in Table 1 , and baseline medications being taken by the participants are shown in Table 2 , both grouped by regression, stability, or progression of TPV. Table V in the online-only Data Supplement shows tertiles of progression of TPV, TPA, and IMT.
The distribution of baseline IMT, TPA, and TPV, and the distribution of change from baseline to 1 year later for the 3 phenotypes are shown in Figure V in the online-only Data Supplement. Data on 1-year progression/regression were available in 323 cases for TPA and in 306 cases for TPV and IMT.
Assessed by Pearson correlation (R), baseline TPV was strongly correlated with TPA (R=0.645; P=0.001), but only weakly correlated with IMT (R=0.189; P=0.001). This is illustrated in Figure VI in the online-only Data Supplement. Accordingly, TPA was also weakly correlated with IMT (R=0.282; P=0.001). However, there was no significant correlation between progression/regression of TPA versus TPV In this population chosen by the presence of substantial plaque, the baseline burden of IMT, TPA, or TPV did not predict events. Survival free of any cardiovascular event (stroke, vascular death, TIA, or MI) and survival free of stroke, TIA, or vascular death were significantly predicted by progression/ regression of TPV, as shown in Figure 1 . In Cox regression analysis (backward stepwise Wald), at the final step (step 9), the only remaining predictors were baseline systolic blood pressure (P=0.086) and progression/regression of TPV (P=0.001).
Participants with progression of TPA from baseline to 1 year later had more events; this approached significance for stroke/death/TIA (P=0.097), as shown in Figure 2 , but not for any CV event (P=0.143). Prediction of any CV event by progression/regression of TPA was intermediate between prediction by TPV and IMT, as shown in Figures VII to IX in the online-only Data Supplement. In Cox regression with TPA change and baseline covariates, only age (P=0.034) and smoking status (P=0.031) remained in the model at the final step (step 7). Similarly, as shown in online supplementary figures 10-12, progression of TPV predicted stroke/death/myocardial infarction (P=0.007), progression of TPA did not (P-0.59), nor did progression of IMT (P=0.13).
However, progression/regression of IMT did not predict stroke/TIA/death as shown in Figure 3 nor did it predict any cardiovascular event ( Figure IX in the online-only Data Supplement). In Cox regression with baseline covariates as listed in Methods, smoking status (P=0.021), triglycerides (P=0.009), high-density lipoprotein cholesterol (P=0.044), and IMT change (P=0.004) were significant predictors of events, but as shown in Figure 3 and Figure IX in the online-only Data Supplement, the relationship to IMT change was inverse because IMT regression was associated with a higher risk of events.
Discussion
To our knowledge, this is the first study of TPV progression as a predictor of cardiovascular outcomes, and the first to compare progression of IMT, TPA, and TPV in the same participants. The Tromsø study 22 compared progression of IMT and TPA with regard to coronary risk factors, but did not measure TPV, and to date have not reported on prediction of events by progression of IMT and TPA. Sillesen et al 14 showed that plaque burden measured by a 3D probe (but not strictly plaque volume, as the probe was moved along the artery) was much more strongly correlated with coronary calcium score than was IMT; they did not measure TPA.
We found that progression of TPV strongly predicted cardiovascular events, and the prediction remained significant after adjustment for coronary risk factors in Cox regression. Surprisingly, it was regression of IMT rather than progression that predicted events, a finding that strengthens the growing consensus that IMT measured in the far wall of the common carotid at a site where there is no plaque should not be regarded as truly representing atherosclerosis. 2, 3, [22] [23] [24] Possible reasons for this finding, and for the weak correlation between IMT and plaque, have been discussed previously 25, 26 ; IMT is a different phenotype that probably represents mainly hypertensive medial hypertrophy, and probably does not truly represent atherosclerosis. 2 Another possible reason is that for technical reasons we measured different segments of the carotid arteries with the 3 methods. Progression of TPA weakly predicted stroke/TIA/death but not the all cardiovascular events, and prediction of risk was not significant after adjustment for coronary risk factors.
A limitation of the study was the relatively small sample, which was determined by the funding available. The a priori sample size calculation had been that 350 participants followed for a mean of 4.7 years would give an adequate sample size to show differences among the ultrasound phenotypes with regard to prediction of cardiovascular events. This was based on data from our 2002 report 15 and was consistent with the sample in a study of TPA, IMT, and endothelial function as predictors of events in patients with coronary artery disease by Chan et al. 27 However, the finding that progression of TPV significantly predicted events in such a small sample supports the contention that measurement of TPV is a powerful tool for assessing clinically relevant effects of therapy.
It should be noted that the study population was powerful, despite its small size, because all participants had substantial carotid plaque, and the number of events was relatively high. In our 2002 study 15 of TPA and TPA progression, in which approximately half the participants had little or no plaque at baseline, there were 166 vascular events among 1686 participants (9.8%) followed for an average of 2.5 years (about as many events as in the first 10 years of the Framingham Heart Study); in this study population, there were first vascular events in 15.8% of participants during a median follow-up of 3.17 years. Table IV in the online-only Data Supplement. The log-rank P value was 0.886 across the 3 groups.
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In 2012, the Rotterdam study 28 and the MESA study 29 both showed that coronary artery calcium, but not IMT, improved risk prediction and risk reclassification beyond a Framingham risk score. Although a single coronary artery calcium might be useful for reclassifying patients to higher risk so that they can be appropriately chosen for more intensive therapy, concern about radiation with repeated scans precludes its use for management of patients. Carotid TPA has been used successfully to treat arteries instead of risk factors, 10 and this approach markedly reduced risk among high-risk patients with asymptomatic carotid stenosis. 30 Brook et al 31 found that TPA was more closely related to coronary stenosis than IMT, coronary calcium, or CRP, and Johri et al 32 found that plaque volume was more sensitive than plaque thickness for prediction of coronary stenosis. Our findings suggest that measurement of TPV will be a useful approach to treating high-risk patients; this hypothesis will need to be tested in a clinical trial. It should be noted that our management of patients was not protocol-based but was based on our previously reported approach 10 to treating arteries instead of treating risk factors.
Measurement of TPV progression will also be useful for computing quantitative traits of atherosclerosis for genetic studies because as previously discussed, 33 age accounts for most of the explained variance in baseline plaque phenotypes, but is only a weak predictor of progression.
As genetic approaches identify new therapeutic targets for atherosclerosis, 34, 35 it will be important to have methods to study effects of new therapies on atherosclerosis as proofof-principle, before going on to very large and costly studies on the basis of reduction of events. Our findings support the recommendation 3 that measurement of TPV is a costeffective way to assess new therapies for atherosclerosis.
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